Abstract
The phenotypic spectrum of myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorders (MOGAD) has broadened in the past few years, and atypical phenotypes are increasingly recognized. Febrile meningoencephalitis has rarely been reported as a feature of MOGAD and represents a diagnostic challenge. We report the case of 24-year-old women with high-grade fever, meningoencephalomyelitis, and persistently positive MOG-IgG, for whom an extensive infectious work-up was negative and who responded to high-dose intravenous methylprednisolone. The full clinical spectrum of MOGAD is yet to be completely elucidated. In patients presenting with febrile meningoencephalitis, MOG-IgG testing should be considered particularly if infectious work-up is negative.
Introduction
Myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorders (MOGAD) represent a unique phenotypic spectrum of demyelinating inflammatory autoimmune disorders of the central nervous system (CNS) which has broadened considerably in the past few years. Typical presentations include optic neuritis (in up to 80% of patients) often bilateral and severe (in around 40% of patients), longitudinally extensive transverse myelitis often confined to the grey matter and/or involving the conus (in up to 50% of patients), and acute disseminated encephalomyelitis (ADEM) (in about 5% of adults and 20% of children with MOGAD). 1 Other rarer phenotypes include seizures and focal cerebral edema (FLAMES), 2 imaging-negative myelitis, 3 brainstem and area postrema syndromes 4 among others, for which MOGAD is more likely to be overlooked. The presence of high fever and meningeal signs in the context of ADEM is not a classical finding of MOGAD and represents a diagnostic challenge, as infectious causes are to be ruled out first and appropriate treatment can be delayed. We report the case of a patient who developed severe MOGAD-related ADEM with high-fever and meningeal signs mimicking infectious meningoencephalomyelitis.
Case presentation
A previously healthy 24-year-old woman presented to the emergency department with a one-week history of severe headache followed by fever (38.5–39 °C) which rapidly worsened 48 h prior to presentation with mild right-sided brachiofacial paresthesia, phonophobia, photophobia, and urinary retention. She reported the consumption of unpasteurized cheese and watery diarrhea two months ago. Physical examination at presentation showed nuchal rigidity, horizontal nystagmus with right gaze, saddle hypoesthesia, and hyperreflexic deep tendon but downgoing plantar reflexes. Initial brain MRI showed subtle abnormalities in the pons and brainstem (Figure 1A). Paraclinical workup is shown in Table 1. A chest, abdomen, and pelvis CT was normal. Intravenous vancomycin, ceftriaxone, and acyclovir were started empirically. Within the next 12 h, she developed persistent high-grade fever (40 °C) over the next 48 h, altered mental status, dysarthria, diplopia, facial diplegia, and severe weakness in bilateral lower extremities. Physical examination was prominent for ophthalmoplegia secondary to bilateral cranial nerve 6 palsy, multidirectional nystagmus, facial diplegia, left pronator drift, decreased strength in left (2/5 proximally, 1/5 distally) and right (3/5 proximally, 4/5 distally) lower extremities, hyperreflexia in all four limbs, bilateral extensor plantar reflexes, and bilateral dysmetria in upper extremities, more prominent on the left. Repeat brain and spinal cord MRI 48 h after presentation showed several lesions in the brainstem, pons, left middle cerebellar peduncles, supratentorial regions, and longitudinally extensive myelitis (Figure 1B–F). Antibiotic therapy was empirically broadened to intravenous ampicillin, ceftriaxone, gentamycin, acyclovir, and oral doxycycline and rifampin. Intravenous methylprednisolone (1 g/day for 8 days) was started 24 h after antimicrobial treatment initiation. MOG-IgG testing using a fixed cell-based assay (MVZ Labor Dr. Limbach and colleagues, Breitspiel, Heidelberg) was positive (titer of 1:160). Antibiotics were discontinued after negative infectious work-up. Progressive clinical improvement was noted 6 days after methylprednisolone initiation. Repeat MRI 10 days after initial imaging showed significant improvement to near resolution of most lesions. Physical examination 45 days after discharge showed complete recovery of strength and cranial nerve function, with persistent obstructive urinary symptoms and subtle spasticity in the left lower extremity.

Brain and spinal cord MRIs at presentation. (A) Axial FLAIR sequences of first brain MRI at presentation, 3 days after symptom onset, showing subtle non-enhancing ill-demarcated abnormalities in the left middle cerebellar peduncle and the pons. No other abnormalities were identified on this MRI. (B) Axial FLAIR sequences of brain MRI 48 h after presentation, 5 days after symptom onset, showing worsening of abnormalities in the pons, bilateral cerebellar peduncles, and 3 new round white matter abnormalities in bilateral cerebral hemispheres suggestive of inflammatory demyelination with (C) enhancement of one of the lesions in the left parietal lobe on axial T1 sequences with gadolinium. Sagittal and axial T2 sequences of (D) cervical and (E) dorsal cord MRIs showing longitudinally extensive myelitis extending from C1 to T12, mainly confined to the grey matter, with (F) a focal faint nodular enhancement at the C7 level and prominent T1 hypointensity throughout the cord on axial T1 sequences with gadolinium.
Serum and cerebrospinal fluid work-up. CSF studies were performed at day 1 and 3 (prior to obtaining MOG-IgG antibody results).
AQP-4: aquaporin-4; CBC: complete blood count; CMP: complete metabolic panel; CMV: cytomegalovirus; CRP: C-reactive protein; CSF: cerebrospinal fluid; EBV: Epstein–Barr virus; ESR: erythrocyte sedimentation rate; HIV: human immunodeficiency virus; HSV: herpes simplex virus; MOG: myelin oligodendrocyte glycoprotein; N: normal; PCR: polymerase chain reaction; RBC: red blood cells; RT-PCR : reverse transcription PCR; SARS-Cov-2: severe acute respiratory syndrome coronavirus 2; VDRL: Venereal Disease Research Laboratory; WBC: white blood cells.
Viral PCR panel in CSF included HSV1, HSV2, VZV, EBV, CMV, HHV6, HHV7, HHV8, human parechovirus, human enterovirus, mumps, and measles.
Bacterial PCR panel in CSF included (Neisseria meningitides, Listeria monocytogenes, Haemophilus influenzae, Streptococcus agalactiae and pneumonia, Escherichia coli, Staphylococcus aureus, Borrelia burgdoferi and miyamotoi.
She was treated with an oral prednisone tapered over five months. Repeat Anti-MOG IgG remained positive six months after initial presentation with a titer of 1:160.
Discussion
The full spectrum of MOGAD continues to broaden as new and atypical presentations are reported in the literature. Diagnostic criteria for MOGAD have been proposed in 2018 by an expert consensus. 5 None of the clinical and neuroimaging findings are highly specific for MOGAD and anti-MOG-IgG testing using cell-based assays is necessary for appropriate diagnosis. After the exclusion of alternate diagnoses, MOGAD is diagnosed based on the presence of a compatible clinical presentation, neuroimaging findings compatible with demyelinating CNS lesions and positive MOG-IgG detected by cell-based assay. 5 Post-infectious MOG-IgG formation has been described, indicating a possible infectious trigger for MOG-autoimmunity. 6
We report an atypical presentation of MOGAD mimicking severe infectious encephalomyelitis. Our patient developed high-grade fever (40 °C), meningeal signs, and encephalomyelitis, particularly a rhombencephalitis presentation on initial MRI. Her history misled us to the possibility of an infectious etiology. CSF analysis showed lymphocytic pleocytosis with hypoglycorrhachia and increased protein. Our differential diagnoses were listeriosis, brucellosis, tuberculosis, and a viral infection, for which broad-spectrum antibiotics and acyclovir were initiated.
Fever is considered a major red flag for the diagnosis of autoimmune CNS disorders and warrants the exclusion of CNS infections. However, a couple of recent papers reports the presence of fever in MOGAD in a significant proportion of patients and concomitant to neurological symptom onset. 7 In a recent review of 146 MOGAD case reports, fever was described in 39%, although not reported in larger descriptive cohorts and review papers. 8
Fever seems to be more frequent in children with MOGAD compared to adults.7, 8 Even in rare severe complications that may occur in MOGAD-related ADEM such as status epilepticus, increased intracranial pressure, and respiratory failure requiring ventilatory support, fever is not mentioned as a key clinical feature. 9 The reason why fever develops in some patient is unclear, but may be explained by CNS infiltration of immune cells with subsequent inflammatory cascades and production of pro-inflammatory cytokines, increased vascular permeability and blood-brain barrier disruption, as well as direct lesions involving the midbrain. 10
In our patient, in light of a negative comprehensive infectious work-up along with a non-response to initial broad-spectrum antibiotic and antiviral treatment and the ADEM-like lesions on brain and spinal cord MRI, post-infectious ADEM, neuromyelitis optica spectrum disorders, and MOGAD were suggested. The presence of fever argued against a classic ADEM, as it represents an exclusionary feature for this diagnosis. She responded within 24 h after initiation of high dose IV solumedrol (1 g per day for 8 days), and continued to improve steadily on a slow oral prednisone taper over the next month. MOG-IgG were positive with persistent positivity at month 6 after oral prednisone discontinuation, confirming the diagnosis of MOGAD. MRI lesions showed significant improvement with near-resolution of most lesions on follow-up scan, further corroborating the diagnosis.
This case highlights that MOGAD should be in the differential diagnosis of adult patients with febrile encephalomyelitis, specifically if the initial infectious work-up is negative, to avoid treatment delay and consequently, worse outcomes.
Footnotes
Acknowledgements
The authors thank the patient for providing consent to publish his case.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: GM served on advisory boards for Genentech-Roche, Novartis, Mercks, and Biologix, received speaker fees from Biologix, Mercks, and Novartis, and participated in educational activities for Neurology Live and John Hopkin's e-Litterature Review.
Ethical considerations
Consent was obtained from the patient for publishing this case report.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
